Longeveron Chief Science Officer Dr. Joshua Hare To Keynote 2018 HEALinc Future Health Innovation Summit
October 05, 2018
Longeveron LLC, a biopharmaceutical company that develops stem cell therapies, announced that Co-Founder and Chief Science Officer Joshua Hare, M.D. will be a keynote speaker at the 2018 HEALincFuture Health Innovation Summit, to be held Oct. 7-9 at the Melia Nassau Beach Hotel, Nassau, Bahamas
NEWS PROVIDED BY
Oct. 05, 2018 09:40 ET
MIAMI, Oct. 5, 2018 /PRNewswire/ — Longeveron LLC, a biopharmaceutical company that develops stem cell therapies, announced that Co-Founder and Chief Science Officer Joshua Hare, M.D. will be a keynote speaker at the 2018 HEALincFuture Health Innovation Summit, to be held Oct. 7-9 at the Melia Nassau Beach Hotel, Nassau, Bahamas.
The inaugural annual event will bring together renowned researchers, clinicians, entrepreneurs, investors and regulators to discuss cutting-edge advancements in regenerative medicine, cellular therapy and emerging healthcare technologies. Dr. Hare also will be presented with a special lifetime achievement award for his pioneering work in stem cell research.
“I am very pleased to be taking part in this first Bahamas HEALinc summit in collaboration with the leading industry experts and innovators who are now working on new therapies that will herald the future of regenerative medicine. The Bahamas is an ideal venue for this summit as it has enacted progressive legislation – with significant regulatory oversight by the National Stem Cell Ethics Committee under the leadership of Dr. Desiree Cox – that recognizes and fosters the great value of regenerative medicine,” Dr. Hare said.
Longeveron is researching treatments based on its Mesenchymal Stem Cells for a variety of aging-related diseases. In 2017, Longeveron published positive Phase I and Phase 2 clinical studies in the Journals of Gerontology that evaluated the safety and efficacy of its Mesenchymal Stem Cells in patients with Aging Frailty, a serious geriatric syndrome that can lead to other severe health conditions, such as heart disease. The company is now recruiting for an expanded Phase 2b Aging Frailty study.
Longeveron is also recruiting for a Phase 1 Alzheimer’s trial, and Phase 1 and 2 trials to evaluate the safety and efficacy of its stem cells for improving flu vaccine immune response in Aging Frailty patients. Longeveron’s MSC product is derived from the bone marrow of young, healthy adult donors.
Longeveron’s MSCs are also approved for use in the Bahamas. As the only company to have a locally-approved allogeneic stem cell treatment, Longeveron currently is conducting a single-arm open label clinical trial for Aging Frailty in the Bahamas and is planning to add other indications to its Bahamas trial including cognitive disorders and orthopedic conditions.
Longeveron (www.longeveron.com) is a regenerative medicine therapy company founded in 2014. Longeveron’s goal is to provide the first of its kind biological solution for aging-related diseases, and is dedicated to developing safe cell-based therapeutics to revolutionize the aging process and improve quality of life. The company’s research focus areas Aging Frailty, the Metabolic Syndrome and Alzheimer’s Disease and gratefully acknowledges the generous support of the National Institutes of Health, the Alzheimer’s Association and Maryland Stem Cell Research Fund. Longeveron is also conducting a Phase 1 trial to study Hypoplastic Left Heart Syndrome, a rare indication that affects infants, supported through a grant from the Maryland Stem Cell Research Fund.
For more information about the clinical trials
Longeveron is sponsoring, visit ClinicalTrials.gov
SOURCE Longeveron LLC